The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

descriptionPublicationkeyboard_double_arrow_right Article 01 Aug 2011 English Publisher:Elsevier BVJournal:Clinics in Liver Disease, volume 15, pages 611-626 (issn: 1089-3261,

Copyright policy )

Authors: Fernando E, Membreno; Eric J, Lawitz;

doi: 10.1016/j.cld.2011.05.003

pmid: 21867940

The HCV NS5B Nucleoside and Non-Nucleoside Inhibitors

- Summary
- Subjects
- Metrics

Abstract

This article introduces one of the most diverse classes of direct-acting antivirals for hepatitis C, the nucleoside and non-nucleoside NS5B polymerase inhibitors. Through a systematic review of the published literature, we describe their structure, mechanism of action, issues with resistance, and clinical effectiveness shown in the latest clinical trials. Direct-acting antiviral combination trials that have already shown some early promising results even in the setting of interferon-sparing antiviral regimens are discussed.

Keywords

Clinical Trials as Topic, Guanosine Monophosphate, Viral Nonstructural Proteins, RNA-Dependent RNA Polymerase, Antiviral Agents, Deoxycytidine, Hepatitis C, Humans, Sofosbuvir, Uridine Monophosphate

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	49
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%